Trials / Withdrawn
WithdrawnNCT05304130
A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab
A Single Center, Single Dose, Open-label Study in Healthy Japanese Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Otilimab
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 20 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the safety, tolerability and pharmacokinetics (PK) profiles of otilimab in healthy Japanese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Otilimab | Otilimab will be administered via pre-filled syringe. |
Timeline
- Start date
- 2023-02-08
- Primary completion
- 2023-05-04
- Completion
- 2023-05-04
- First posted
- 2022-03-31
- Last updated
- 2023-01-26
Source: ClinicalTrials.gov record NCT05304130. Inclusion in this directory is not an endorsement.